# US 10,246,516 B2 · Anti-La antibodies and their use for immunotargeting

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 10,246,516 B2
- Document ID: US10246516B2
- Status: Granted
- Kind: B2
- Application number: 15/355,060
- Filed: 2016-11-18
- Published: 2017-06-08
- Granted: 2019-04-02
- Earliest claimed: 2010-08-06
- Assignees: GEMoaB Monoclonals GmbH
- Applicants: GEMoaB Monoclonals GmbH
- Inventors: Michael Bachmann
- Web page: https://patentgrep.com/patent/US10246516B2

## CPC

- C07K 16/30: from tumour cells
- C07K 16/18: against material from animals or humans
- C07K 16/2809: {against the T-cell receptor (TcR)-CD3 complex}
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/31: multispecific
- C07K 2317/34: Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C07K 2317/54: F(ab')2
- C07K 2317/56: variable (Fv) region, i.e. VH and/or VL
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/622: Single chain antibody (scFv)
- C07K 2317/626: Diabody or triabody
- C07K 2317/73: Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The invention relates to antibodies against the human La protein and to their use in immunotargeting, in particular the immunotargeting of tumor cells. The object of the invention is to provide improved antibodies which bind universal target structures on the surface of tumor cells, and to provide novel anti-La antibodies, in particular with a high affinity for La, a universal target structure on tumor cells, which make it possible to use the antibodies as recombinant fragments for immunotargeting. The invention comprises recombinant antibodies comprising: (i) a binding unit of an antibody which specifically binds to an epitope of a human nuclear antigen, preferably human La protein, and (ii) a binding unit of an antibody which specifically binds to an effector cell or of a ligand which specifically binds to an effector cell. The invention furthermore comprises novel antibodies which specifically bind the human La protein.

## Claims

### Claim 1

Recombinant antibody, comprising
(a) a binding unit of a first antibody that specifically binds to an epitope of a human nuclear antigen, wherein one such human nuclear antigen can comprise human La, characterized in that the first antibody is an antibody which binds specifically an epitope of the human La protein (anti-La antibody) containing regions determining complementarity (complementarity determining regions, CDRs), the CDRs of the variable region of the light chain (V L) and the variable region of the heavy chain (V H) comprising the following sequences:
SEQ
SEQ
ID
ID
VL
No.
VH
No.
CDR1
RSSQSLLDSRTRKNYLA
9
DFWMN
10
CDR2
WASTRES
11
QIRNKPNNYETYYSDSLKG
12
CDR3
KQSYNLPT
13
LGNSWFAY
14
and
(b) a binding unit comprising:
a second antibody which binds specifically to an effector cell or
a ligand which binds specifically to an effector cell.

### Claim 2 (depends on 1)

The recombinant antibody according to claim 1, characterized in that the second antibody or the ligand which binds specifically to an effector cell is selected from antibodies and ligands which bind specifically surface structures on T lymphocytes, NK cells and/or monocytes.

### Claim 3 (depends on 1)

The recombinant antibody according to claim 1 containing the following, optionally humanized, structure:
a variable region of the light chain having a sequence of SEQ ID No. 53 and
a variable region of the heavy chain having a sequence of SEQ ID No. 54.

### Claim 4 (depends on 1)

The recombinant antibody according to claim 1, in the form of a scFv fragment, a F(ab′)2 fragment, diabodies, triabodies or tetrabodies.

### Claim 5

Antibodies which bind specifically an epitope of the human La protein (anti-La antibody) containing regions determining complementarity (complementarity determining regions, CDRs), characterized in that the CDRs of the variable region of the light chain (VL) and the variable region of the heavy chain (VH) comprise the following sequences:
SEQ
SEQ
ID
ID
VL
No.
VH
No.
CDR1
RSSQSLLDSRTRKNYLA
9
DFWMN
10
CDR2
WASTRES
11
QIRNKPNNYETYYSDSLKG
12
CDR3
KQSYNLPT
13
LGNSWFAY
14

### Claim 6 (depends on 5)

The antibodies according to claim 5, containing the following, optionally humanized, structure:
a variable region of the light chain having a sequence of SEQ ID No. 53 and
a variable region of the heavy chain having a sequence of SEQ ID No. 54.

### Claim 7 (depends on 5)

The antibodies according to claim 5 in the form of a scFv fragment, a F(ab′)2 fragment, diabodies, triabodies or tetrabodies.